Donepezil Hydrochloride; Memantine Hydrochloride Patent Expiration
Donepezil Hydrochloride; Memantine Hydrochloride is Used for managing moderate to severe dementia in Alzheimer's disease. It was first introduced by Abbvie Inc
Donepezil Hydrochloride; Memantine Hydrochloride Patents
Given below is the list of patents protecting Donepezil Hydrochloride; Memantine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Namzaric | US8058291 | Methods and compositions for the treatment of CNS-related conditions | Dec 05, 2029 | Abbvie |
| Namzaric |
US8039009 (Pediatric) | Modified release formulations of memantine oral dosage forms | Sep 24, 2029 | Abbvie |
| Namzaric | US8039009 | Modified release formulations of memantine oral dosage forms | Mar 24, 2029 | Abbvie |
| Namzaric |
US8168209 (Pediatric) | Method and composition for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namzaric |
US8173708 (Pediatric) | Method and composition for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namzaric |
US8283379 (Pediatric) | Methods and compositions for the treatment of CNS-related conditions | May 22, 2026 | Abbvie |
| Namzaric |
US8329752 (Pediatric) | Composition for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namzaric |
US8362085 (Pediatric) | Method for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namzaric |
US8598233 (Pediatric) | Method for administering an NMDA receptor antagonist to a subject | May 22, 2026 | Abbvie |
| Namzaric | US8168209 | Method and composition for administering an NMDA receptor antagonist to a subject | Nov 22, 2025 | Abbvie |
| Namzaric | US8173708 | Method and composition for administering an NMDA receptor antagonist to a subject | Nov 22, 2025 | Abbvie |
| Namzaric | US8283379 | Methods and compositions for the treatment of CNS-related conditions | Nov 22, 2025 | Abbvie |
| Namzaric | US8293794 | Methods and compositions for the treatment of CNS-related conditions | Nov 22, 2025 | Abbvie |
| Namzaric | US8329752 | Composition for administering an NMDA receptor antagonist to a subject | Nov 22, 2025 | Abbvie |
| Namzaric | US8338485 | Compositions for the treatment of CNS-related conditions | Nov 22, 2025 | Abbvie |
| Namzaric | US8338486 | Methods for the treatment of CNS-related conditions | Nov 22, 2025 | Abbvie |
| Namzaric | US8362085 | Method for administering an NMDA receptor antagonist to a subject | Nov 22, 2025 | Abbvie |
| Namzaric | US8580858 | Compositions for the treatment of CNS-related conditions | Nov 22, 2025 | Abbvie |
| Namzaric | US8598233 | Method for administering an NMDA receptor antagonist to a subject | Nov 22, 2025 | Abbvie |
| Namzaric |
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct 11, 2015
(Expired) | Abbvie |
| Namzaric | US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr 11, 2015
(Expired) | Abbvie |
Donepezil Hydrochloride; Memantine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Donepezil Hydrochloride; Memantine Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Donepezil Hydrochloride; Memantine Hydrochloride. The first generic version for Donepezil Hydrochloride; Memantine Hydrochloride was by Amneal Pharmaceuticals Llc and was approved on Jan 27, 2017. And the latest generic version is by Amneal Pharmaceuticals Llc and was approved on Feb 27, 2025.
Given below is the list of companies who have filed for Donepezil Hydrochloride; Memantine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL
Amneal Pharmaceuticals Llc has filed for 4 different strengths of generic version for Donepezil Hydrochloride; Memantine Hydrochloride. All of these versions come by the name MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG; 28MG | capsule, extended release | Prescription | ORAL | AB | Jan 27, 2017 |
| 10MG; 14MG | capsule, extended release | Prescription | ORAL | AB | Jan 27, 2017 |
| 10MG; 7MG | capsule, extended release | Prescription | ORAL | AB | Feb 27, 2025 |
| 10MG; 21MG | capsule, extended release | Prescription | ORAL | AB | Feb 27, 2025 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
2. ANI PHARMS
Ani Pharmaceuticals Inc has filed for 1 generic for Donepezil Hydrochloride; Memantine Hydrochloride. This 10mg;21mg version comes by the name MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Ani Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG; 21MG | capsule, extended release | Prescription | ORAL | AB | Dec 15, 2023 |